** Life science and clinical research company Bruker Corp BRKR.O shares down about 5.9% at $35.75 in early trading
** Lowers FY 2025 adj. EPS between $1.95 - $2.05 from prior expectations of $2.40 - $2.48
** Trims FY 2025 revenue outlook to $3.43 bln - $3.50 bln from previous target of $3.48 bln - $3.44 bln
** Expanded cost savings initiative expects to cut annual costs by $100-$120 mln in FY 2026
** Misses Q2 revenue and adj. profit estimates, hurt by challenging demand conditions in the U.S. academic market
** "Tariffs and stiff currency headwind could not be compensated by mitigating price, supply chain and cost actions in Q2." - CEO Laukien
** Stocks down 35.19% YTD
(Reporting by Aditi Tiwari in Bengaluru)
((Aditi.Tiwari@thomsonreuters.com))